CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Acute myeloid leukemias (AMLs) often have poor prognoses, particularly high-risk cases.
• Mechanisms by which AMLs co-opt stem cell gene regulatory programs are poorly understood.
• Increased MECOM expression is a key driver in incurable AMLs, but its role in aggressive phenotypes is unknown.

Purpose of the Study:

• To elucidate the mechanisms by which MECOM drives aggressive AML phenotypes.
• To identify therapeutic strategies targeting MECOM-driven leukemogenesis.

Main Methods:

• Engineered and applied targeted protein degradation combined with functional genomic readouts.
• Investigated MECOM's direct impact on gene regulatory programs.
• Analyzed a specific MECOM-bound cis-regulatory element downstream of CEBPA.

Main Results:

• MECOM promotes malignant stem cell-like states by repressing pro-differentiation gene regulatory programs.
• A single MECOM-bound cis-regulatory element is necessary and sufficient for maintaining MECOM-driven leukemias.
• Targeted activation of this element induced AML cell differentiation and reduced leukemia burden in vivo.

Conclusions:

• MECOM's repression of differentiation programs is a key mechanism in aggressive AML.
• A specific cis-regulatory element is a critical vulnerability in MECOM-driven AML.
• Targeting this element offers a potential differentiation-based therapy for AML.